Market Prognosis

A concise summary of the major macro events of the past 24 hours, and selected UK company-specific news.

<< Back to Market PROGnosis archive

May 17, 2023

The “trading weighted towards H2” trend

Macro & Overnight

US competition authorities are attempting to block the Amgen and Horizon merger, citing concerns over the impact on US drug prices.

Despite the looming debt ceiling, precious metals have weakened, and the US $ has strengthened.

UK Company News

There is a discernable trend of companies updating that they are on track but with a greater weighting towards H2, so technically, they are a bit off-track. Investors need to be careful about what indicators there are for a more robust H2 performance in any update. 

Coats, the industrial thread and global footwear component manufacturer, updated trading in line with expectations. It saw a revenue decline of 7% and down 20% in constant exchange rates. It expects a second-half weighting, underpinned by the contribution from acquisitions, associated synergies and strategic projects. Profit margins were resilient, supported by strategic projects and tight cost control.

Gamma Communications sees its trading outcome within the forecast range. (See note here).  

Mpac, the packaging machinery supplier, said that momentum from Q4 2022 has continued into 2023. Its order intake and the volume of quotation activity are all significantly above the prior year. Results are expected to be weighted towards the year’s second half, with the current order book providing extensive coverage over the revenue forecast.

Watch retailer, Watches of Switzerland reported FY23 performance in line with guidance. It said it enters FY24 significantly ahead of its Long Range Plan. It anticipates that the more challenging trading environment of the second half of FY23 will continue into the first half of FY24 before improving in H2. 

Prognosticator 

This communication is provided for information purposes only, and is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. Investors should seek advice from an Independent Financial Adviser or regulated stockbroker before making any investment decisions. Progressive Equity Research Ltd (“PERL”) does not make investment recommendations.

Opinions contained in this communication represent those of PERL and/or our affiliates at the time of publication and PERL does not undertake to provide updates to any opinions or views expressed. PERL does not hold any positions in the securities mentioned in this communication, however, PERL’s directors, officers, employees, contractors and affiliates may hold a position,  and/or may perform services or solicit business from, any of the companies or related securities mentioned.

Any prices quoted in our research are as at the previous day’s close.